
European Journal of Heamatology
Fecha de publicación: 1 october 2018
DOI: https://doi.org/10.1111/ejh.13179
Autores: Larysa Poluben MD., Maneka Puligandla MS., Donna Neuberg ScD., Christine R. Bryke MD., Yahsuan Hsu MS., Oleksandr Shumeiko MD., Xin Yuan MD, DSc., et al.
Background: Acute myeloid leukemia (AML) can be subtyped based on recurrent cytogenetic and molecular genetic abnormalities with diagnostic and prognostic significance. Although cytogenetic characterization classically involves conventional chromosome and/or fluorescence in situ hybridization (FISH) assays, limitations of these techniques include poor resolution and the inability to precisely identify breakpoints.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.